How many Mounjaro (tirzepatide) pens should be ordered for a 90‑day supply?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mounjaro 90-Day Supply Ordering

For a 90-day supply of Mounjaro, order 12 pens (or 12 vials if using the vial formulation).

Dosing Schedule

Mounjaro (tirzepatide) is administered once weekly 1. Since there are approximately 13 weeks in a 90-day period, you need:

  • 12-13 pens for a true 90-day supply
  • Standard packaging comes in boxes of 4 single-dose pens 1

Practical Ordering Approach

Order 3 boxes (12 pens total) to cover a 90-day period. This provides 12 weekly doses, which covers approximately 84 days. Most insurance plans and pharmacies structure 90-day supplies this way.

If you need to cover the full 13 weeks (91 days), you would technically need 13 pens, but standard practice is to order in multiples of the 4-pen boxes.

Available Formulations

Each box contains 4 single-dose prefilled pens in the following strengths 1:

  • 2.5 mg/0.5 mL
  • 5 mg/0.5 mL
  • 7.5 mg/0.5 mL
  • 10 mg/0.5 mL
  • 12.5 mg/0.5 mL
  • 15 mg/0.5 mL

Vial option: Single-dose vials are also available in the same strengths (requires separate needles and syringes) 1.

Dose Escalation Considerations

Most patients (84.1%) initiate at ≤5 mg doses 2. During the first 6 months, 69.6% of patients have at least one dose escalation, with mean time to first escalation of 59.1 days 2. When ordering a 90-day supply, consider whether the patient will remain on the same dose throughout or require dose titration, which would necessitate ordering different strength boxes.

References

Research

Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United States.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025

Related Questions

Can Mounjaro (tirzepatide) injections be administered every 10 days instead of the approved weekly schedule?
For a patient undergoing spinal cord stimulator implantation, what are the instructions for stopping and restarting tirzepatide?
In a patient on tirzepatide (Zepbound) for three months who now has mild right breast tenderness around the nipple with no palpable mass, should the medication be continued and how should the breast symptoms be managed?
What counseling points should be provided to a patient starting tirzepatide (Mounjaro) therapy?
What questions should be asked and what key factors should be evaluated during an initial consultation for a patient being considered for tirzepatide (Zepbound) therapy?
In patients with pulmonary arterial hypertension receiving Winrevair (sotatercept) alongside background endothelin‑receptor antagonist and phosphodiesterase‑5 inhibitor therapy, how long does it typically take to see improvement in symptoms and a reduction in mean pulmonary artery pressure (mPAP)?
What is the appropriate management for eye redness that develops after starting trimethoprim‑sulfamethoxazole (Bactrim)?
Can ramelteon (Rozerem) be discontinued abruptly without tapering?
Can you summarize the phase III KEYNOTE‑689 trial results of peri‑operative pembrolizumab (programmed death‑1 inhibitor) in patients with resectable locally advanced head‑and‑neck squamous cell carcinoma?
How should a syncopal episode in a teenage female be evaluated and managed?
Why do I experience a calming effect from guanfacine on the first day but not thereafter?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.